Cybin (CYBN) Competitors $7.02 +0.01 (+0.14%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$6.99 -0.03 (-0.43%) As of 05/21/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CYBN vs. KROS, IMTX, TYRA, VALN, MRVI, RLAY, GHRS, STOK, KURA, and OPTShould you be buying Cybin stock or one of its competitors? The main competitors of Cybin include Keros Therapeutics (KROS), Immatics (IMTX), Tyra Biosciences (TYRA), Valneva (VALN), Maravai LifeSciences (MRVI), Relay Therapeutics (RLAY), GH Research (GHRS), Stoke Therapeutics (STOK), Kura Oncology (KURA), and Opthea (OPT). These companies are all part of the "pharmaceutical products" industry. Cybin vs. Keros Therapeutics Immatics Tyra Biosciences Valneva Maravai LifeSciences Relay Therapeutics GH Research Stoke Therapeutics Kura Oncology Opthea Cybin (NYSE:CYBN) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Do institutionals & insiders have more ownership in CYBN or KROS? 17.9% of Cybin shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 20.6% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has preferable valuation and earnings, CYBN or KROS? Cybin has higher earnings, but lower revenue than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.38-1.60Keros Therapeutics$214.71M2.66-$152.99M-$0.18-78.00 Do analysts rate CYBN or KROS? Cybin presently has a consensus price target of $86.00, indicating a potential upside of 1,125.07%. Keros Therapeutics has a consensus price target of $37.00, indicating a potential upside of 163.53%. Given Cybin's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cybin is more favorable than Keros Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Keros Therapeutics 0 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.57 Does the media favor CYBN or KROS? In the previous week, Keros Therapeutics had 3 more articles in the media than Cybin. MarketBeat recorded 9 mentions for Keros Therapeutics and 6 mentions for Cybin. Cybin's average media sentiment score of 1.30 beat Keros Therapeutics' score of 1.15 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in CYBN or KROS? Keros Therapeutics received 50 more outperform votes than Cybin when rated by MarketBeat users. However, 100.00% of users gave Cybin an outperform vote while only 70.53% of users gave Keros Therapeutics an outperform vote. CompanyUnderperformOutperformCybinOutperform Votes17100.00% Underperform VotesNo VotesKeros TherapeuticsOutperform Votes6770.53% Underperform Votes2829.47% Is CYBN or KROS more profitable? Cybin has a net margin of 0.00% compared to Keros Therapeutics' net margin of -27,890.94%. Cybin's return on equity of -37.58% beat Keros Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Keros Therapeutics -27,890.94%-41.74%-38.42% Which has more volatility and risk, CYBN or KROS? Cybin has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. SummaryCybin beats Keros Therapeutics on 10 of the 18 factors compared between the two stocks. Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYBN vs. The Competition Export to ExcelMetricCybinPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$150.77M$6.52B$5.37B$19.41BDividend YieldN/A2.65%5.22%3.83%P/E Ratio-1.608.9226.8434.23Price / SalesN/A253.80392.3434.85Price / CashN/A65.8538.2517.51Price / Book0.656.466.794.69Net Income-$57.88M$143.98M$3.23B$1.02B7 Day Performance10.03%3.04%4.07%-1.34%1 Month Performance-3.70%7.44%12.52%9.79%1 Year PerformanceN/A-2.46%16.83%3.27% Cybin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYBNCybin2.7174 of 5 stars$7.02+0.1%$86.00+1,125.1%N/A$150.77MN/A-1.6050Positive NewsKROSKeros Therapeutics3.2288 of 5 stars$13.74+0.7%$37.00+169.3%-72.2%$558.05M$214.71M-2.64100IMTXImmatics2.8222 of 5 stars$4.56+7.5%$16.67+265.5%-51.8%$554.27M$155.84M-6.91260News CoveragePositive NewsTYRATyra Biosciences1.6737 of 5 stars$10.26+1.7%$30.83+200.5%-47.1%$544.70MN/A-6.3720News CoveragePositive NewsAnalyst ForecastAnalyst RevisionVALNValneva2.0997 of 5 stars$6.45-0.3%$15.50+140.3%-22.2%$539.45M$169.58M-49.62700MRVIMaravai LifeSciences4.0798 of 5 stars$2.12+7.1%$6.34+199.2%-79.5%$539.19M$259.19M-1.29610RLAYRelay Therapeutics3.3081 of 5 stars$3.11+3.7%$17.67+468.1%-62.2%$533.19M$7.68M-1.19330GHRSGH Research2.5349 of 5 stars$10.16-2.1%$30.43+199.5%-4.6%$528.60MN/A-12.8610STOKStoke Therapeutics3.4811 of 5 stars$9.66+3.2%$25.60+165.0%-38.2%$527.41M$36.56M-4.60100Positive NewsAnalyst RevisionGap UpKURAKura Oncology4.3075 of 5 stars$6.09+5.7%$23.89+292.3%-72.0%$527.24M$67.99M-2.58130News CoverageAnalyst ForecastAnalyst RevisionOPTOpthea0.671 of 5 stars$3.41+7.2%$1.33-60.9%+1.8%$524.84M$87,666.000.008Gap Up Related Companies and Tools Related Companies KROS Competitors IMTX Competitors TYRA Competitors VALN Competitors MRVI Competitors RLAY Competitors GHRS Competitors STOK Competitors KURA Competitors OPT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CYBN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYBN Stock Free CYBN Stock Alerts